A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

Amarendra Pegu; Bhavesh Borate; Yunda Huang; Matthias G. Pauthner; Ann J. Hessell; Boris Julg; Nicole A. Doria-Rose; Stephen D. Schmidt; Lindsay N. Carpp; Michelle D. Cully; Xuejun Chen; George M. Shaw; Dan H. Barouch; Nancy L. Haigwood; Lawrence Corey; Dennis R. Burton; Mario Roederer; Peter B. Gilbert; John R. Mascola; Ying Huang

doi:10.1016/j.chom.2019.08.014

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

Amarendra Pegu, Bhavesh Borate, Yunda Huang, Matthias G. Pauthner, Ann J. Hessell, Boris Julg, Nicole A. Doria-Rose, Stephen D. Schmidt, Lindsay N. Carpp, Michelle D. Cully, Xuejun Chen, George M. Shaw, Dan H. Barouch, Nancy L. Haigwood, Lawrence Corey, Dennis R. Burton, Mario Roederer, Peter B. Gilbert, John R. Mascola, Ying Huang

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection. With data from multiple non-human primate SHIV challenge studies that used single bNAbs, we conducted a meta-analysis to examine the relationship between predicted serum 50% neutralization titer (ID50) against the challenge virus and infection outcome. In a logistic model that adjusts for bNAb epitopes and challenge viruses, serum ID50 had a highly significant effect on infection risk (p < 0.001). The estimated ID50 to achieve 50%, 75%, and 95% protection was 91 (95% confidence interval [CI]: 55, 153), 219 (117, 410), and 685 (319, 1471), respectively. This analysis indicates that serum neutralizing titer against the relevant virus is a key parameter of protection and that protection from acquisition by a single bNAb might require substantial levels of neutralization at the time of exposure.

Original language	English (US)
Pages (from-to)	336-346.e3
Journal	Cell Host and Microbe
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/j.chom.2019.08.014
State	Published - Sep 11 2019

Keywords

SHIV challenge
broad neutralizing antibodies
correlates of protection
meta-analysis
non-human primate studies

ASJC Scopus subject areas

Parasitology
Microbiology
Virology

Access to Document

10.1016/j.chom.2019.08.014

Fingerprint Dive into the research topics of 'A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge'. Together they form a unique fingerprint.

Cite this

Pegu, A., Borate, B., Huang, Y., Pauthner, M. G., Hessell, A. J., Julg, B., Doria-Rose, N. A., Schmidt, S. D., Carpp, L. N., Cully, M. D., Chen, X., Shaw, G. M., Barouch, D. H., Haigwood, N. L., Corey, L., Burton, D. R., Roederer, M., Gilbert, P. B., Mascola, J. R., & Huang, Y. (2019). A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. Cell Host and Microbe, 26(3), 336-346.e3. https://doi.org/10.1016/j.chom.2019.08.014

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. / Pegu, Amarendra; Borate, Bhavesh; Huang, Yunda; Pauthner, Matthias G.; Hessell, Ann J.; Julg, Boris; Doria-Rose, Nicole A.; Schmidt, Stephen D.; Carpp, Lindsay N.; Cully, Michelle D.; Chen, Xuejun; Shaw, George M.; Barouch, Dan H.; Haigwood, Nancy L.; Corey, Lawrence; Burton, Dennis R.; Roederer, Mario; Gilbert, Peter B.; Mascola, John R.; Huang, Ying.

In: Cell Host and Microbe, Vol. 26, No. 3, 11.09.2019, p. 336-346.e3.

Research output: Contribution to journal › Article

Pegu, A, Borate, B, Huang, Y, Pauthner, MG, Hessell, AJ, Julg, B, Doria-Rose, NA, Schmidt, SD, Carpp, LN, Cully, MD, Chen, X, Shaw, GM, Barouch, DH, Haigwood, NL, Corey, L, Burton, DR, Roederer, M, Gilbert, PB, Mascola, JR & Huang, Y 2019, 'A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge', Cell Host and Microbe, vol. 26, no. 3, pp. 336-346.e3. https://doi.org/10.1016/j.chom.2019.08.014

Pegu, Amarendra ; Borate, Bhavesh ; Huang, Yunda ; Pauthner, Matthias G. ; Hessell, Ann J. ; Julg, Boris ; Doria-Rose, Nicole A. ; Schmidt, Stephen D. ; Carpp, Lindsay N. ; Cully, Michelle D. ; Chen, Xuejun ; Shaw, George M. ; Barouch, Dan H. ; Haigwood, Nancy L. ; Corey, Lawrence ; Burton, Dennis R. ; Roederer, Mario ; Gilbert, Peter B. ; Mascola, John R. ; Huang, Ying. / A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. In: Cell Host and Microbe. 2019 ; Vol. 26, No. 3. pp. 336-346.e3.

@article{7ff44e5f3801497d867134bb4f1a5077,

title = "A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge",

abstract = "Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection. With data from multiple non-human primate SHIV challenge studies that used single bNAbs, we conducted a meta-analysis to examine the relationship between predicted serum 50% neutralization titer (ID50) against the challenge virus and infection outcome. In a logistic model that adjusts for bNAb epitopes and challenge viruses, serum ID50 had a highly significant effect on infection risk (p < 0.001). The estimated ID50 to achieve 50%, 75%, and 95% protection was 91 (95% confidence interval [CI]: 55, 153), 219 (117, 410), and 685 (319, 1471), respectively. This analysis indicates that serum neutralizing titer against the relevant virus is a key parameter of protection and that protection from acquisition by a single bNAb might require substantial levels of neutralization at the time of exposure.",

keywords = "SHIV challenge, broad neutralizing antibodies, correlates of protection, meta-analysis, non-human primate studies",

author = "Amarendra Pegu and Bhavesh Borate and Yunda Huang and Pauthner, {Matthias G.} and Hessell, {Ann J.} and Boris Julg and Doria-Rose, {Nicole A.} and Schmidt, {Stephen D.} and Carpp, {Lindsay N.} and Cully, {Michelle D.} and Xuejun Chen and Shaw, {George M.} and Barouch, {Dan H.} and Haigwood, {Nancy L.} and Lawrence Corey and Burton, {Dennis R.} and Mario Roederer and Gilbert, {Peter B.} and Mascola, {John R.} and Ying Huang",

year = "2019",

month = sep,

day = "11",

doi = "10.1016/j.chom.2019.08.014",

language = "English (US)",

volume = "26",

pages = "336--346.e3",

journal = "Cell Host and Microbe",

issn = "1931-3128",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

AU - Pegu, Amarendra

AU - Borate, Bhavesh

AU - Huang, Yunda

AU - Pauthner, Matthias G.

AU - Hessell, Ann J.

AU - Julg, Boris

AU - Doria-Rose, Nicole A.

AU - Schmidt, Stephen D.

AU - Carpp, Lindsay N.

AU - Cully, Michelle D.

AU - Chen, Xuejun

AU - Shaw, George M.

AU - Barouch, Dan H.

AU - Haigwood, Nancy L.

AU - Corey, Lawrence

AU - Burton, Dennis R.

AU - Roederer, Mario

AU - Gilbert, Peter B.

AU - Mascola, John R.

AU - Huang, Ying

PY - 2019/9/11

Y1 - 2019/9/11

N2 - Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection. With data from multiple non-human primate SHIV challenge studies that used single bNAbs, we conducted a meta-analysis to examine the relationship between predicted serum 50% neutralization titer (ID50) against the challenge virus and infection outcome. In a logistic model that adjusts for bNAb epitopes and challenge viruses, serum ID50 had a highly significant effect on infection risk (p < 0.001). The estimated ID50 to achieve 50%, 75%, and 95% protection was 91 (95% confidence interval [CI]: 55, 153), 219 (117, 410), and 685 (319, 1471), respectively. This analysis indicates that serum neutralizing titer against the relevant virus is a key parameter of protection and that protection from acquisition by a single bNAb might require substantial levels of neutralization at the time of exposure.

AB - Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection. With data from multiple non-human primate SHIV challenge studies that used single bNAbs, we conducted a meta-analysis to examine the relationship between predicted serum 50% neutralization titer (ID50) against the challenge virus and infection outcome. In a logistic model that adjusts for bNAb epitopes and challenge viruses, serum ID50 had a highly significant effect on infection risk (p < 0.001). The estimated ID50 to achieve 50%, 75%, and 95% protection was 91 (95% confidence interval [CI]: 55, 153), 219 (117, 410), and 685 (319, 1471), respectively. This analysis indicates that serum neutralizing titer against the relevant virus is a key parameter of protection and that protection from acquisition by a single bNAb might require substantial levels of neutralization at the time of exposure.

KW - SHIV challenge

KW - broad neutralizing antibodies

KW - correlates of protection

KW - meta-analysis

KW - non-human primate studies

UR - http://www.scopus.com/inward/record.url?scp=85071461255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071461255&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2019.08.014

DO - 10.1016/j.chom.2019.08.014

M3 - Article

C2 - 31513771

AN - SCOPUS:85071461255

VL - 26

SP - 336-346.e3

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

IS - 3

ER -